{"id":"W4393343265","doi":"10.1007/s00262-024-03654-0","title":"Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research; Boehringer Ingelheim","keywords":"Medicine; Adverse effect; Pharmacokinetics; Internal medicine; Maximum tolerated dose; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003040913,0.000621932,0.0009403289,0.0006416133,0.0001653521,0.0001050947,0.0004297557,0.0003540831,0.001004932],"category_scores_gemma":[0.00001145604,0.0005006949,0.000233899,0.001072191,0.0005939625,0.0006282094,0.00004508842,0.0007807086,0.00005045127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006705765,"about_ca_system_score_gemma":0.0006964633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004655237,"about_ca_topic_score_gemma":0.00009708535,"domain_scores_codex":[0.9967847,0.0001447274,0.0007425047,0.000966595,0.0003916814,0.0009697296],"domain_scores_gemma":[0.9984631,0.00007125413,0.0001752015,0.0009899224,0.0001962527,0.0001042548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.03643753,0.001536645,0.2245396,0.0002069881,0.00258808,0.000228673,0.002169483,0.00006450949,0.4058591,0.0001836939,0.0004051349,0.3257806],"study_design_scores_gemma":[0.01974919,0.004753898,0.9297491,0.001225712,0.0001147358,0.00007317583,0.0003315959,0.0000957321,0.01512304,0.00006600642,0.02788705,0.0008308018],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9263381,0.06875535,0.0001047675,0.001232344,0.001616306,0.001124374,0.00006978564,0.000365864,0.0003930865],"genre_scores_gemma":[0.9811528,0.01573699,0.0003067121,0.001457139,0.000140336,0.0002456208,0.0003130932,0.0002018532,0.0004453994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7052095,"threshold_uncertainty_score":0.9999083,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009003923693406368,"score_gpt":0.3100422142431986,"score_spread":0.3010382905497923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}